Rathke Cleft Cyst — a benign, non-neoplastic, epithelium-lined cystic lesion arising from remnants of the Rathke pouch, the embryonic ectodermal outgrowth that gives rise to the anterior pituitary gland and pars intermedia during fetal development, forming when the epithelial lining of the craniopharyngeal canal fails to regress completely between the eighth and tenth weeks of gestation and instead persists as a mucin-secreting or serous-fluid-containing cystic structure situated within the sella turcica at the boundary between the anterior and posterior pituitary lobes, occasionally extending into the suprasellar cistern above the diaphragma sellae, and characterized on pathological examination by a simple epithelial lining composed of columnar, cuboidal, or ciliated epithelium with goblet cells producing intracystic mucoid material that is variably thick, viscous, and gelatinous or thin and watery depending on the predominant epithelial cell type — represents one of the most common incidental sellar findings on modern MRI neuroimaging, with autopsy series and large retrospective MRI cohort studies estimating the prevalence of Rathke cleft cysts at thirteen to thirty-three percent of unselected adult populations, the vast majority of which are entirely asymptomatic microlesions discovered incidentally during imaging obtained for unrelated indications. The minority of Rathke cleft cysts that become clinically significant do so through one of three principal mechanisms: hormonal disruption through compression of the adjacent anterior pituitary gland and infundibular stalk, producing hypopituitarism with deficiencies of growth hormone, gonadotropins, thyroid-stimulating hormone, and adrenocorticotropic hormone in various combinations, as well as hyperprolactinemia from stalk compression interrupting the dopaminergic inhibition of lactotroph function; visual pathway compromise through suprasellar extension of the cyst compressing the optic chiasm, producing bitemporal hemianopia or monocular visual field defects; and headache from expansion within the confined sella turcica producing dural traction. Diagnostic evaluation relies primarily on MRI with and without gadolinium, which characterizes the cyst signal — variably T1 hyperintense from mucoid proteinaceous content, T2 hypointense or hyperintense depending on protein concentration, without peripheral gadolinium enhancement in the absence of inflammation or prior aspiration — and distinguishes Rathke cleft cysts from craniopharyngioma, which shows calcification and cyst wall enhancement, and from pituitary adenoma, which shows solid enhancing tissue and a different hormonal profile. Hormonal evaluation includes a complete anterior pituitary hormone panel, prolactin level, and morning cortisol to characterize the degree of hypopituitarism and determine which hormone replacement therapies are required. Treatment for symptomatic Rathke cleft cysts is transsphenoidal surgical drainage and partial cyst wall resection via endoscopic or microscopic transsphenoidal approach, with recurrence rates of fifteen to thirty percent necessitating long-term surveillance neuroimaging regardless of whether surgery is performed.
Rathke Cleft Cyst technology platforms — whether supporting pituitary endocrinology platforms managing the comprehensive hormonal evaluation, hypopituitarism replacement therapy titration, and longitudinal pituitary function surveillance for patients with symptomatic Rathke cleft cysts; neuroradiology platforms providing the serial sellar MRI studies with dynamic pituitary gadolinium sequences and high-resolution coronal T2 imaging essential to monitoring cyst size and detecting cyst growth or recurrence after transsphenoidal drainage; endoscopic transsphenoidal neurosurgery platforms coordinating the operative planning, intraoperative fluoroscopy and MRI guidance, and endoscopic instrumentation for transsphenoidal cyst drainage; visual field testing platforms managing the perimetry programs that monitor optic chiasm decompression or ongoing compression in patients with suprasellar extension; hormone replacement management platforms supporting the long-term glucocorticoid, thyroid, growth hormone, and gonadal steroid replacement programs for patients with Rathke cleft cyst-associated hypopituitarism; and patient communication platforms delivering surveillance MRI scheduling, medication adherence support, and adrenal insufficiency emergency action plan education to patients on glucocorticoid replacement — must maintain the availability and performance standards that serial sellar neuroimaging, endocrine laboratory monitoring, transsphenoidal surgical planning, visual field surveillance, hormone replacement management, and patient safety education demand. This guide explains why Rathke Cleft Cyst tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the pituitary endocrinology, serial neuroimaging, transsphenoidal surgical coordination, visual pathway monitoring, and hormone replacement demands of modern Rathke Cleft Cyst care.
Why Rathke Cleft Cyst Tech Platforms Require Specialized Monitoring Attention
Rathke Cleft Cyst management is defined by three platform-dependent priorities that reflect the condition's neuroendocrine complexity, serial neuroimaging surveillance requirements, and the critical patient safety needs of hypopituitarism management: the requirement for pituitary endocrinology platforms capable of comprehensive hormonal assessment, replacement therapy titration, and the dynamic stimulation testing that characterizes the degree of corticotroph and somatotroph deficiency requiring glucocorticoid and growth hormone replacement; neuroradiology platforms providing the specialized sellar MRI with dynamic pituitary gadolinium sequences and volumetric cyst measurements necessary for serial size comparison, recurrence detection after transsphenoidal drainage, and optic chiasm decompression confirmation; and patient safety platforms ensuring that patients on glucocorticoid replacement for Rathke cleft cyst-associated adrenal insufficiency have uninterrupted access to their adrenal crisis action plans, sick-day rules, and emergency hydrocortisone injection protocols.
Pituitary endocrinology platforms are essential for hormone management and safety. Endocrinology clinic platforms providing access to serial anterior pituitary hormone panels, dynamic stimulation test results, hormone replacement dosing records, and adrenal insufficiency management protocols are the clinical management infrastructure for Rathke cleft cyst programs; failures during an endocrinology clinic encounter for a patient with Rathke cleft cyst-associated panhypopituitarism and adrenal insufficiency who reports worsening headache, fatigue, and nausea since reducing their hydrocortisone dose prevent the endocrinologist from accessing the recent morning cortisol, ACTH stimulation test result, and current replacement regimen required to determine whether the patient is experiencing relative adrenal insufficiency requiring dose adjustment or is developing cyst-related pituitary deterioration requiring urgent MRI and neurosurgical evaluation. Monitor pituitary endocrinology platforms at 1-minute intervals during clinic sessions.
Neuroradiology platforms support surveillance and recurrence detection. MRI platforms providing serial sellar imaging with dynamic gadolinium pituitary sequences, high-resolution coronal T2 weighted imaging for cyst wall and infundibular stalk visualization, and volumetric cyst size measurements for comparison with prior studies are the surveillance infrastructure for Rathke cleft cyst monitoring; failures during a surveillance MRI for a patient who underwent transsphenoidal drainage eighteen months prior and is being evaluated for cyst recurrence prevent the neuroradiologist from completing the comparison review that determines whether the re-accumulating cyst volume has returned to the threshold associated with symptomatic optic chiasm compression and recurrent hypopituitarism requiring repeat surgical intervention. Monitor neuroradiology platforms at 1-minute intervals during imaging sessions.
Patient safety platforms protect patients on glucocorticoid replacement. Patient portal platforms delivering adrenal insufficiency sick-day rules, stress dosing protocols, emergency hydrocortisone injection instructions, and medical alert card documentation to patients with Rathke cleft cyst-associated corticotroph deficiency are the patient safety infrastructure for a condition where adrenal crisis during physiological stress — surgery, febrile illness, trauma — is life-threatening; failures prevent patients from accessing the specific instructions specifying when to double hydrocortisone dose, when to inject intramuscular emergency hydrocortisone, and when to present to an emergency department, directly increasing the risk of unrecognized and untreated adrenal crisis. Monitor patient safety platforms 24/7.
What to Monitor on a Rathke Cleft Cyst Tech Platform
Pituitary Endocrinology and Hormone Management Platforms
Monitor pituitary endocrinology clinic records for Rathke cleft cyst hormone surveillance (anterior pituitary hormone panel results including IGF-1, free T4, TSH, LH, FSH, testosterone or estradiol, and morning cortisol; dynamic stimulation test records including insulin tolerance test, glucagon stimulation test, or ACTH stimulation test results characterizing corticotroph and somatotroph reserve; growth hormone replacement dose titration records and IGF-1 response monitoring; thyroid hormone replacement records with free T4 target range documentation; gonadal steroid replacement records; hyperprolactinemia surveillance records for patients with stalk compression hyperprolactinemia), adrenal insufficiency management records including hydrocortisone dosing schedules and sick-day rule education, and pituitary endocrinology scheduling platforms at 1-minute intervals during clinic sessions. Alert immediately — endocrinology platform failures during a clinic encounter for a patient with Rathke cleft cyst-associated panhypopituitarism prevent the endocrinologist from reviewing the ACTH stimulation test peak cortisol response and current hydrocortisone replacement dose before adjusting therapy for a patient who reports that their fatigue, dizziness, and nausea have been worsening on their current replacement regimen, a presentation that requires integration of the complete hormonal profile before any replacement adjustment is made safely.
Neuroradiology and Sellar Imaging Platforms
Monitor sellar MRI records for Rathke cleft cyst surveillance studies (cyst signal characteristics on T1 and T2 weighted sequences, presence and intensity of T1 hyperintensity from intracystic proteinaceous mucoid content, gadolinium enhancement pattern to exclude cyst wall enhancement suggesting xanthogranulomatous reaction or secondary neoplastic transformation, infundibular stalk visualization and deviation assessment, optic chiasm position and signal relative to suprasellar cyst extension, pituitary gland volume and signal to assess compressive atrophy, and comparison measurements against all prior sellar MRI studies in the surveillance series), dynamic pituitary gadolinium sequence records documenting the timing and degree of normal versus delayed pituitary gland enhancement, visual field perimetry records for patients with suprasellar extension, and neuroradiology platforms at 1-minute intervals during imaging sessions and 2-minute intervals during radiologic review hours. Alert immediately — neuroradiology platform failures during a surveillance sellar MRI review for a patient with a known suprasellar Rathke cleft cyst prevent the neuroradiologist from accessing the prior imaging series to compare optic chiasm displacement and cyst volume against the current study, which is the primary evidence base for the neurosurgical referral decision for a patient who has developed new-onset bitemporal visual symptoms since the last surveillance imaging.
Transsphenoidal Neurosurgery Planning Platforms
Monitor transsphenoidal neurosurgery pre-operative records (pre-operative sellar MRI loaded into surgical planning system, intraoperative fluoroscopy or MRI guidance protocol documentation, endoscope trajectory planning for transsphenoidal approach to sellar cyst, sphenoid sinus pneumatization assessment relevant to transsphenoidal corridor selection, pituitary gland preservation planning documentation, and suprasellar extension access planning for cysts extending above the diaphragma sellae), intraoperative fluoroscopy or navigation records during transsphenoidal drainage procedures, post-operative MRI records documenting cyst drainage adequacy and residual cyst wall, and neurosurgical planning platforms at 1-minute intervals during transsphenoidal procedures. Alert immediately — neurosurgical planning platform failures during a transsphenoidal endoscopic Rathke cleft cyst drainage prevent the neurosurgeon from accessing the intraoperative fluoroscopy or MRI guidance overlay confirming the endoscope position within the sphenoid sinus and the sellar floor anatomy relative to the cyst cavity at the critical moment when the sellar floor must be opened and the cyst must be entered without injury to the adjacent carotid arteries, optic nerves, and residual pituitary gland tissue.
Visual Field and Ophthalmology Platforms
Monitor visual field perimetry records for patients with suprasellar Rathke cleft cyst extension (automated Humphrey visual field or Goldmann perimetry documentation characterizing the bitemporal hemianopia pattern, temporal crescent involvement, and any monocular visual field defects; pre-operative and post-operative visual field comparison for surgical candidates; visual acuity and color vision records; fundoscopic records for optic disc pallor from chronic compression), and ophthalmology scheduling platforms during business hours. Alert on sustained failures — visual field and ophthalmology platform outages prevent the neuro-ophthalmologist from accessing the serial visual field records to compare the current perimetry with the pre-operative baseline and the three-month post-operative study for a patient who had transsphenoidal Rathke cleft cyst drainage for optic chiasm compression and now reports subjective visual deterioration that may represent recurrent cyst expansion with progressive chiasmal compression.
Hormone Replacement Pharmacy and Dispensing Platforms
Monitor pharmacy dispensing records for Rathke cleft cyst hormone replacement medications (hydrocortisone or cortisone acetate dispensing records for corticotroph deficiency, levothyroxine dispensing records for thyrotroph deficiency, testosterone or estradiol dispensing records for gonadotroph deficiency, recombinant growth hormone dispensing and supply chain records for patients on growth hormone replacement, desmopressin dispensing records for patients with concomitant diabetes insipidus from posterior pituitary involvement), and pharmacy platform availability during business hours. Alert on sustained failures — pharmacy platform outages prevent the endocrinology nurse coordinator from confirming that the hydrocortisone prescription for a patient with Rathke cleft cyst-associated adrenal insufficiency has been dispensed and that the patient's emergency hydrocortisone injection kit has been refilled, which is a patient safety verification function for a patient who is about to undergo elective knee surgery requiring perioperative glucocorticoid stress dosing.
Patient Safety and Education Platforms
Monitor patient portal records for Rathke cleft cyst patient safety communication (adrenal insufficiency sick-day rules specifying the exact clinical circumstances requiring hydrocortisone dose doubling, intramuscular emergency injection, or emergency department presentation; stress dosing protocols for fever, gastrointestinal illness, and surgical procedures; medical alert card documentation for adrenal insufficiency; surveillance MRI scheduling reminders; hormone replacement adherence support; and visual symptom warning instructions specifying the visual field changes warranting urgent neuro-ophthalmology or neurosurgery evaluation), and patient communication platforms 24/7. Alert on sustained failures — patient portal outages for a patient with Rathke cleft cyst-associated adrenal insufficiency who is acutely unwell with gastroenteritis and unable to retain oral hydrocortisone prevent access to the emergency injection protocol and the guidance specifying that inability to take oral hydrocortisone due to vomiting requires immediate intramuscular injection or emergency department presentation — a life-threatening access failure for a patient at risk of adrenal crisis.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Rathke Cleft Cyst programs coordinate across pituitary endocrinology, neurosurgery, neuroradiology, neuro-ophthalmology, pharmacy, and patient communication platforms — authentication failures block access to the hormonal testing records central to endocrine management, the sellar imaging records required for surveillance and surgical planning, the hormone replacement medication records essential to safe dose management, and the patient safety education platforms delivering adrenal crisis emergency protocols to patients with life-threatening hypopituitarism.
SSL Certificates
Monitor SSL certificate expiry across all sellar neuroimaging platforms, endocrinology clinic systems, transsphenoidal surgical planning platforms, visual field testing systems, pharmacy dispensing platforms, and patient safety portal platforms. Certificate errors disrupt serial MRI surveillance access, hormonal testing record retrieval, transsphenoidal operative planning imaging, visual field comparison review, pharmacy verification, and the patient safety communication infrastructure central to Rathke Cleft Cyst management.
HIPAA and Data Privacy Considerations
Rathke Cleft Cyst technology platforms handle PHI including serial sellar MRI records characterizing cyst dimensions, intracystic mucoid content characteristics, optic chiasm compression, and infundibular stalk involvement; anterior pituitary hormone panel results documenting the specific pattern of hypopituitarism including growth hormone deficiency with IGF-1 levels, gonadotroph deficiency with sex steroid levels, thyrotroph deficiency with free T4 values, and corticotroph deficiency with cortisol and ACTH stimulation test results; dynamic stimulation test records documenting peak hormone responses; hormone replacement medication records including hydrocortisone dosing schedules, growth hormone injection logs, and thyroid hormone titration; visual field perimetry records documenting chiasmal compression defects; operative records for transsphenoidal drainage; and patient safety records including adrenal insufficiency emergency action plans and stress dosing protocols.
The particular sensitivity of Rathke Cleft Cyst PHI includes the endocrine deficiency records — which document hormonal function data with implications for occupational eligibility determinations, insurance coverage assessments, and reproductive counseling decisions that extend well beyond the immediate clinical context — and the adrenal insufficiency management records, which describe life-threatening medical vulnerabilities that require careful access control given their implications for patient privacy and the risk that disclosure of adrenal crisis vulnerability could be exploited in employment, insurance, or personal safety contexts. Technology platforms managing Rathke Cleft Cyst PHI must implement HIPAA Security Rule requirements for availability and integrity across all record types, with particular attention to the hormonal deficiency documentation, adrenal insufficiency emergency protocols, and surgical records. Availability monitoring provides operational documentation relevant to HIPAA Security Rule compliance for pituitary endocrinology, neurosurgery, neuroradiology, and neuro-ophthalmology departments managing Rathke Cleft Cyst care.
Alerting Strategy for Rathke Cleft Cyst Tech Platforms
Immediate alerting during transsphenoidal surgery: Intraoperative fluoroscopy, neuronavigation, and endoscopic imaging platforms during transsphenoidal cyst drainage procedures — intraoperative guidance platform availability is a patient safety requirement when the endoscope is positioned at the sellar floor adjacent to carotid arteries, optic nerves, and residual pituitary tissue.
Immediate alerting during surveillance neuroimaging: Sellar MRI platforms during scheduled surveillance sessions — timely comparison access determines the clinical disposition of the surveillance encounter and the neurosurgical referral decision.
24/7 alerting for patient safety platforms: Patient portal platforms delivering adrenal insufficiency emergency protocols and sick-day rules — adrenal crisis risk is continuous and life-threatening, and access failures are patient safety events at any hour.
Sustained-failure alert (10–15 minutes): Pituitary endocrinology clinic and hormone management platforms; pharmacy dispensing platforms for hormone replacement medications; visual field and neuro-ophthalmology platforms; pre-operative transsphenoidal surgical planning platforms.
Sustained-failure alert (15–30 minutes): Surveillance scheduling and patient education platforms for the conservatively managed asymptomatic majority.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms Rathke Cleft Cyst platform availability from the geographies where pituitary endocrinology centers, transsphenoidal neurosurgery programs, neuroradiology departments, and neuro-ophthalmology clinics manage the hormonal, surgical, and visual surveillance of patients with Rathke cleft cysts.
Status Page for Rathke Cleft Cyst Care Team Communication
A real-time status page gives pituitary endocrinologists reviewing hormone replacement regimens for patients with Rathke cleft cyst-associated hypopituitarism, transsphenoidal neurosurgeons accessing pre-operative sellar MRI before an endoscopic cyst drainage procedure, neuroradiologists comparing serial sellar imaging for recurrence surveillance, neuro-ophthalmologists reviewing visual field progression in patients with suprasellar extension, pharmacists verifying hormone replacement dispensing and emergency kit refills, and patient safety educators managing adrenal insufficiency emergency protocol delivery immediate platform visibility without requiring IT support contact. During a neuroradiology platform outage when the neurosurgeon needs to review the surveillance MRI demonstrating cyst re-accumulation and progressive optic chiasm compression before deciding whether to proceed with repeat transsphenoidal drainage — and the clinical team must confirm cyst volume progression against the post-operative baseline before a time-sensitive operative decision — a status page enables immediate identification of the outage and escalation to backup imaging access procedures without delay.
Include the status page URL in pituitary endocrinology downtime protocols, neuroradiology department downtime procedures, transsphenoidal surgery suite downtime protocols, pharmacy system downtime procedures, and patient safety communication fallbacks.
Vigilmon Setup for Rathke Cleft Cyst Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Sellar MRI / neuroradiology surveillance | 1 min | Slack + PagerDuty (imaging hours) | | Transsphenoidal surgical planning / intraoperative guidance | 1 min | Slack + PagerDuty (operative hours) | | Pituitary endocrinology / hormone management | 1 min | Slack + PagerDuty (clinic hours) | | Patient safety portal / adrenal insufficiency emergency protocols | 1 min | Slack + PagerDuty (24/7) | | Visual field / neuro-ophthalmology | 2 min | Slack (business hours) | | Pharmacy / hormone replacement dispensing | 2 min | Slack + PagerDuty (business hours) | | Surveillance scheduling / patient education | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure sellar MRI and neuroradiology platforms with immediate alerting during imaging sessions — surveillance imaging comparison is central to recurrence detection and neurosurgical referral decisions
- Add transsphenoidal surgical planning and intraoperative guidance platforms with immediate alerting during operative hours — intraoperative imaging access is a patient safety requirement during endoscopic navigation adjacent to carotid arteries and optic nerves
- Configure pituitary endocrinology platforms with immediate alerting during clinic sessions — hormonal assessment and replacement titration decisions require uninterrupted record access
- Add patient safety portal platforms with 24/7 immediate alerting — adrenal insufficiency emergency protocols and sick-day rules are patient safety functions with no permissible downtime for at-risk patients
- Configure visual field and neuro-ophthalmology platforms with sustained-failure alerting for chiasmal compression surveillance
- Add pharmacy platforms with sustained-failure alerting for hormone replacement dispensing and emergency kit verification
- Configure surveillance scheduling platforms with sustained-failure alerting for the asymptomatic and conservatively managed population
- Enable SSL certificate monitoring across all sellar imaging, endocrinology, surgical planning, pharmacy, and patient safety portal domains
- Add the status page URL to pituitary endocrinology, neuroradiology, transsphenoidal surgery, and patient safety communication downtime protocols
Conclusion
Rathke Cleft Cyst technology platforms are embedded in clinical decisions where pituitary endocrinology platform availability during a hormone management encounter for a patient with Rathke cleft cyst-associated panhypopituitarism who presents with nausea, hypotension, and altered mentation — where the endocrinologist must access the ACTH stimulation test result, current hydrocortisone dose, and recent morning cortisol to determine whether the presentation represents adrenal crisis requiring intravenous hydrocortisone, another hormonal replacement deficiency, or cyst-related pituitary deterioration requiring urgent imaging — cannot be interrupted by a platform failure that prevents accessing the hormonal testing history and replacement records at the moment when the treatment decision must be made; where neuroradiology platform availability during a surveillance sellar MRI review for a patient who underwent transsphenoidal Rathke cleft cyst drainage two years prior and now presents with recurrent headache and new visual field complaints — where the neuroradiologist must measure the re-accumulating cyst volume against the post-operative baseline and the most recent surveillance imaging to determine whether cyst recurrence has reached the threshold of optic chiasm compression requiring neurosurgical referral for repeat drainage — cannot be interrupted by an imaging platform failure that prevents loading the comparison studies at the critical decision point; and where patient safety portal availability for a patient with Rathke cleft cyst-associated adrenal insufficiency who is febrile with gastroenteritis and unable to retain oral hydrocortisone at two in the morning — where the patient needs to access the specific emergency action plan specifying that intramuscular hydrocortisone injection is required when vomiting prevents oral replacement and that emergency department presentation is mandatory if the injection is not available — cannot be interrupted by a portal failure that leaves a patient in potential adrenal crisis without the emergency protocol they need to protect their life. A sellar imaging platform that fails during a recurrence surveillance decision that determines whether a patient with a re-expanding cyst receives timely neurosurgical referral, an endocrinology system inaccessible when hormonal replacement decisions are made for a patient with panhypopituitarism, a patient safety portal unavailable when emergency adrenal crisis guidance reaches a patient with life-threatening corticotroph deficiency — these are not IT incidents. They are clinical disruptions in the management of a common sellar lesion where the endocrine replacement requirements, intraoperative safety demands of transsphenoidal surgery near carotid arteries and optic nerves, and patient safety needs of adrenal insufficiency make every technology supporting the hormonal assessment, operative guidance, and patient safety communication chain a direct determinant of whether patients with Rathke Cleft Cyst receive the safe and effective care this prevalent sellar condition requires.
Uptime monitoring gives Rathke Cleft Cyst tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to pituitary endocrinology practices, transsphenoidal neurosurgery programs, neuroradiology centers, neuro-ophthalmology clinics, and compliance auditors that platform operational reliability matches the hormonal surveillance demands, intraoperative safety requirements of transsphenoidal surgery, serial neuroimaging needs, visual pathway monitoring obligations, and patient safety requirements of modern Rathke Cleft Cyst management.
Start monitoring your Rathke Cleft Cyst care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #rathkecleftcyst #sellarcyst #pituitarytumor #hypopituitarism #transsphenoidal #pituitarysurgery #neuroendocrinology #adrenalinsufficiciency #growth #hormonereplacement #opticchiasm #visualfield #MRI #sellarMRI #HIPAA #healthtech #digitalhealth #uptime #sre